Number of shares and voting rights of Innate Pharma as at August 4, 2017
August 8, 2017Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...Issuance by Innate Pharma of 3,343,748 ordinary shares to Novo Nordisk A/S in consideration for rights in anti-C5aR
July 13, 2017The acquisition of the anti-C5aR, a first-in-class clinical-stage antibody, announced on June 2, 2017, is now finalized; The 3,343,748 new ordinary shares have been issued to Novo Nordisk A/S at a...Results of Annual General Meeting and changes to Innate Pharma’s governance and management team
June 26, 2017All proposed resolutions were voted according to management’s recommendations; Bpifrance Participations, represented by Maïlys Ferrere, and Pr. Jean-Charles Soria were appointed to the Supervisory...Dose-escalation data show favorable safety profile and promising clinical activity for IPH4102
June 15, 2017Oral presentation on the dose-escalation part of a Phase I trial at the International Conference on Malignant Lymphoma (ICML) in Lugano; IPH4102 was evaluated in elderly and heavily pretreated...Innate Pharma strengthens its proprietary pipeline with the acquisition of anti-C5aR, a first-in-class clinical-stage antibody,from novo Nordisk A/S
June 2, 2017Anti-C5a receptor (C5aR) is a first-in-class clinical-stage monoclonal antibody (mAb) targeting myeloid-derived suppressor cells (MDSC) and neutrophils in the tumor microenvironment; Innate Pharma...Innate Pharma to hold its Annual General Meeting of shareholders on June 23, 2017
May 23, 2017Proposals to appoint Supervisory board members and renew members’ mandates at the Annual General Meeting. Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual...
